Peer-Reviewed Review Maps Kratom's Neurocircuitry: Opioid, Dopamine, and Cognitive Impacts

Why it matters

This review offers the most current scientific synthesis of how kratom alkaloids affect brain circuits — directly relevant to ongoing DEA scheduling debates that hinge on whether kratom's pharmacology resembles classic opioids.

The big picture

Published in Current Opinion in Physiology (Elsevier), this review consolidates recent preclinical and clinical research on how kratom's 54+ alkaloids interact with opioid, dopaminergic, and serotonergic systems. While most evidence remains preclinical, the paper identifies mechanisms underlying both therapeutic potential and risk — with particular attention to biased opioid receptor signaling, a property that may distinguish kratom from classical opioids.

Key findings

• Kratom contains at least 54 alkaloids; mitragynine accounts for 40-66% of total alkaloid content, with 7-OH at lower concentrations but higher potency at mu-opioid receptors
• Mitragynine and 7-OH are G-protein-biased partial agonists at the mu-opioid receptor — activating analgesic pathways without fully recruiting beta-arrestin-2, the pathway linked to respiratory depression in classical opioids
• At low doses, kratom produces stimulant effects; at higher doses, analgesic and sedative effects via dopaminergic, serotonergic, and adrenergic pathways
• Chronic use can remodel the dopamine reward system, increasing risk of compulsive use — though effects are less pronounced than morphine
• Higher doses linked to cognitive impairment and possible hepatotoxicity, with confounding by concurrent substance use complicating clinical interpretation
• The authors identify translational research gaps — most evidence is preclinical, with limited well-controlled human clinical studies

What they say

Kratom exhibits considerable pharmacological complexity, with its effects on neurocircuitry, behaviour and cognition arising from the interplay of numerous bioactive alkaloids that may produce complementary or opposing actions across multiple neurobiological targets. — Yunusa et al., Current Opinion in Physiology, 2026

Bottom line

**This peer-reviewed review confirms kratom alkaloids produce opioid-like effects via biased receptor signaling, but also highlights major research gaps — underscoring the need for human clinical trials before regulatory decisions are made on permanent scheduling.**